Technology | March 30, 2009

Atherotech Unveils New Cardiometabolic Test Panels

March 30, 2009 – At ACC 2009, Atherotech Inc., developer of the VAP Cholesterol Test, debuted new cardiovascular and metabolic testing panels.

Atherotech is adding more than a dozen new tests, including C-Reactive Protein (hsCRP), ApoE genotype and NT-proBNP, for assessment of patients at intermediate to high risk of cardiometabolic diseases. The company is also adding advanced and follow-up cardiovascular disease (CVD) risk profiles.

"We're maximizing the value of our core VAP technology with additional cardiometabolic tests," said Atherotech president Michael Mullen. "This provides physicians and cardiology practices with a single source for the VAP Cholesterol Test plus the new test panels. You get the complete cardiovascular and metabolic view."

The VAP Test, which recently added apoAI (and the apoB/apoAI ratio) to its panel, uses advanced lipid profile testing in the identification of individuals at increased risk of heart disease. The new test panels enable Atherotech to increase its scientific and diagnostic capabilities by offering much more complete cardiometabolic testing.

Steven Margolis, M.D., FAAFP, DABCL, a board-certified lipidologist who currently uses the VAP Test for advanced lipid testing of patients in his Sterling Heights, MI, practice, says the new testing panels add significant benefits for practices such as his.

"It's very convenient for physicians to be able to get these heart disease risk factor tests grouped together and not have to deal with multiple reference labs," Dr. Margolis said. "They're also now offering specialized tests such as apoE genetic testing and NT-proBNP that aren't offered by most other reference laboratories."

The new test panels are available immediately and also include homocysteine, creatinine, creatine kinase (CK), HbA1c, TSH, ALT, AST, urea nitrogen (BUN), glucose, vitamin D, fibrinogen and insulin. The tests can be ordered individually, or bundled as part of a custom risk profile that may also include the VAP Test.

The VAP Test provides researchers and medical professionals with direct measurement of LDL, HDL and all relevant subclasses, and includes non-HDL, a highly accurate determination of apoB, and emerging risk factors such as Lp(a), remnants and small dense LDL. The VAP (Vertical Auto Profile) Test is reportedly now the only single cholesterol test that routinely reports apoAI, apoB, and the apoB/apoAI ratio.

For more information: www.atherotech.com, www.thevaptest.com

Related Content

HHS Releases Second Edition of Physical Activity Guidelines for Americans
News | Cardiac Diagnostics | November 14, 2018
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines...
ACC and AHA Release Updated Cholesterol Guidelines for 2018. #AHA18 #AHA2018
Feature | Cardiac Diagnostics | November 13, 2018
November 13, 2018 — New cholesterol guidelines from the American Heart Association (AHA) and the American College of
AMI READMITS Score Predicts Heart Attack Patients at High Readmission Risk
News | Cardiac Diagnostics | October 09, 2018
Tracking just seven factors of heart attack patients when they are first admitted to the hospital can help flag those...
Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Cardiac Diagnostics | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Being Overweight May Change Young Adults' Heart Structure, Function
News | Cardiac Diagnostics | August 03, 2018
Even as a young adult, being overweight may cause higher blood pressure and thicken heart muscle, setting the stage for...
Overlay Init